Abstract. Nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies and is typically treated with radiotherapy and chemotherapy. Garcinone C, a natural compound isolated from Garcinia oblongifolia Champ., is a xanthone derivative with potential cytotoxic effects on certain cancers. However, there are limited studies regarding its effects on NPC cells, and its mechanism of action in NPC remains unknown. In the present study, we found that garcinone C significantly inhibited cell viability of the human NPC cell lines CNE1, CNE2, HK1 and HONE1. This inhibition was exerted in a time-and dose-dependent manner. Flow cytometry demonstrated that garcinone C arrested the cell cycle at the S phase. Moreover, with 10 µM of high-dose garcinone C treatment, the cells exhibited necrotic morphology changes including cell swelling, rough endoplasmic reticulum degranulation, endoplasmic reticulum dilatation, mitochondrial swelling and vacuolar degeneration. In addition, we found that garcinone C stimulated the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, CDK7 and Stat3. Collectively, the ability of garcinone C to inhibit NPC in growth in vitro suggested that garcinone C may be a novel agent for the management of NPC.
Introduction
Malignancies remain a major challenge to global public health (1) . One of the most common head and neck malignancies worldwide, especially in southern China, Southeast Asia, and North Africa, is nasopharyngeal carcinoma (NPC) (2) . There are three subtypes of NPC, classified by the World Health Organization, that include squamous cell carcinoma, non-keratinizing carcinoma and undifferentiated carcinoma (3) .
Radiotherapy is the standard treatment for early-stage NPC, but chemotherapy is also very important in the standard treatment of locally advanced and metastatic NPC. The common chemotherapies used to treat NPC are cisplatin, carboplatin, 5-fluorouracil, gemcitabine, paclitaxel, anthracyclines, bleomycin, epirubicin and cetuximab (2) . However, one of the major obstacles in successfully treating advanced NPC is the development of drug resistance, which can result from a variety of factors, including increased DNA damage tolerance (4). Because of this major obstacle that drug resistance poses, new and better treatment options for NPC are urgently needed.
In the last few decades, natural compounds have gained increasing attention as a source of potential anticancer agents. Xanthones are oxygen-containing heterocyclic compounds widely distributed in various plants and microorganisms. It is well known that xanthones have remarkable pharmacological effects, such as anticancer, antioxidant, anti-inflammatory, antidiabetic, antimicrobial, antithrombotic and hepatoprotective activities (5) (6) (7) . Among them, the anticancer potential of xanthones has drawn an increasing amount of attention. For example, some xanthones, such as gambogic acid (8) (9) (10) (11) (12) and α-mangostin (13) (14) (15) (16) , have been shown to exhibit anticancer properties, including antiproliferation, antiangiogenesis and antimetastasis.
Garcinone C (C 23 H 26 O 7 , MW 414.5, Fig. 1 ), a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia Champ. (a traditional Chinese medicine) that is used as an anti-inflammatory, analgesia, astringency and (17) . However, the function and molecular mechanism of this compound in cell growth and cell cycle progression have not been yet elucidated. In the present study, CNE1 (well-differentiated squamous cell carcinoma), CNE2 (non-keratinizing carcinoma), HK1 (well-differentiated squamous cell carcinoma) and HONE1 (undifferentiated carcinoma) NPC cells were treated with different concentrations of garcinone C and then subjected to biochemical, microscopic, flow cytometric, and molecular analyses to determine the efficacy and mechanism of action of garcinone C in NPC.
Materials and methods
Plant material. Cell culture. Human NPC cell lines CNE1, CNE2, HK1, and HONE1 were a kind gift of Dr Chao-Nan Qian (Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China). Cells were cultured at 37˚C, in a humidified atmosphere with 5% CO 2, in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, 100 U/ml penicillin, 100 µg/ml of streptomycin and 0. 25 Colony formation assay. Cells were diluted and seeded at 500 cells per well in 6-well plates. The following day, CNE1 and HK1 cells were treated with 0.625 and 0.9375 µM garcinone C or DMSO, and CNE2 and HONE1 cells were treated with 1.25 and 2.5 µM garcinone C or DMSO. Medium was replaced with fresh medium containing garcinone C every 4 days. After incubation for 10 days, colonies were fixed with 4% paraformaldehyde for 20 min, visualized with crystal violet, and then scanned with Canon CanoScan 9000F Color Image Scanner. Visible colonies were counted. Colony formation rate (%) = number of colonies/number of seeded cells x 100%. Cell cycle analysis. CNE1, CNE2, HK1 and HONE1 cells were treated with 5, 7.5 and 10 µM of garcinone C or 1/2,000 DMSO for 24, 48 and 72 h. Harvested cells were washed with DPBS and stained with PI according to the protocol of the Cycletest™ Plus DNA Reagent kit (BD Biosciences). Cell cycle distribution was analyzed using the BD Accuri C6 flow cytometer. Approximately 30,000 events were collected per sample. The results were further analyzed using ModFit LT software (Verity Software House Inc., Topsham, ME, USA).
Transmission electron microscopy (TEM).
To investigate and study the cell damage caused by garcinone C, CNE1 and HONE1 cells were respectively cultured with 10 µM garcinone C or DMSO for 24, 48 and 72 h. After washing with DPBS, the cells were fixed with 1 ml of 3% glutaraldehyde and stored at 4˚C. Cells were then washed three times with phosphate-buffered saline (PBS) and further postfixed with 1% osmium tetroxide for 1-2 h. After rinsing three times with PBS, the cells were dehydrated in a graded series of 50, 70 and 90% ethanol and then 90% ethanol:90% acetone (1:1), 90% acetone, and three times with 100% acetone. After dehydration, the cells were embedded in epoxy resin 618 for sectioning. Ultrathin sections were obtained using a Leica EM UC7 ultramicrotome (Leica Microsystems, Buffalo Grove, IL, USA). After staining with uranyl acetate and lead citrate, the sections were examined and photographed with a Hitachi H-7650 transmission electron microscope (Hitachi, Tokyo, Japan).
Protein isolation and western blot analysis. Cells were treated with 5, 7.5 and 10 µM of garcinone C for 24, 48 and 72 h. Cell lysates were prepared in RIPA lysis buffer supplemented with a protease inhibitor cocktail, Phenylmethylsulfonyl fluoride, and Phosphatase Inhibitors Cocktail 2 and 3, and then stored at 4˚C overnight. Total lysates were centrifuged for 20 min, at 13,523 x g at 4˚C, and the supernatant was collected and stored at -80˚C. The quantitative analysis of protein was determined using the Pierce BCA Protein Assay Reagent Kit (Thermo Fisher Scientific, Rockford, IL, USA) and 50 µg of protein was used for SDS-PAGE electrophoresis. Antibodies against cyclin B1 (#4138), cyclin D1 (#2926), cyclin E2 (#4132), cdc2 (#9112), CDK7 (#2916), GAPDH (#2118), Atg3 (#3415), AKT (#9272), Stat5 (#9358), Stat3 (#9139), 4E-BP1 (#9644), mTOR (#2972), GSK-3β (#9315), AMPKα (#2532), Histone H2B (#12364), anti-rabbit IgG (#7074), and anti-mouse IgG (#7076) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-DNA PKcs [Y393] (ab32566) and anti-ATR antibodies (ab10312) were purchased from Abcam (Cambridge, MA, USA). GAPDH was used as an equal loading control. Thermo Scientific Pierce ECL Western Blotting Substrate (Rockford, IL, USA) and Kodak X-OMAT BT Film (Kodak, Rochester, NY, USA) were used to detect the bound immune complexes. The films were then developed by a Kodak X-OMAT 2000 Processor and scanned with a Canon CanoScan 9000F Color Image Scanner (Canon, Melville, NY, USA).
Statistical analysis. All experiments were repeated at least three times. Statistical significance of the differences between two samples was evaluated by the unpaired two-tailed Student's t-test. Significance was established at * P<0.05 or ** P<0.01. Statistical significance of the differences among samples was assessed by one-way analysis of variance followed by the least significant difference and Student-Neumann-Keuls post hoc comparison. The analyses were performed with SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). The threshold of significance was defined as P<0.05.
Results

Garcinone C inhibits the cell viability of human NPC cells in a time-and dose-dependent manner.
To investigate the effect of garcinone C on the viability of the human NPC cell lines CNE1, CNE2, HK1 and HONE1, the cells were treated with garcinone C at a concentration ranging from 0 to 20 µM for 24, 48 and 72 h. After exposure to garcinone C, cell viability was determined using an MTS assay. The results showed that garcinone C treatment inhibited cell viability in these four cell lines in a time-and dose-dependent manner (Fig. 2) . The IC 50 value of garcinone C after 72 h of incubation was 10.68±0.89, 13.24±0.20, 9.71±1.34 and 8.99±1.15 µM for CNE1, CNE2, HK1 and HONE1 cells, respectively. Paclitaxel, an antitumor drug that is known to inhibit cell viability, was used as a positive control for the MTS assay. As shown in Fig. 2 , paclitaxel robustly inhibited cell viability in the CNE1 and HONE1 cells, in a time-and dose-dependent manner, with a 72 h IC 50 of 5.72±1.43 and 3.5±0.80 nM.
Garcinone C reduces the colony-formation ability of human NPC cells.
To further demonstrate the anticancer effects of garcinone C, the colony formation ability of NPC cells after treatment with garcinone C was assessed. CNE1 and HK1 cells were treated with 0.625 or 0.9375 µM of garcinone C for 10 days, while CNE2 and HONE1 cells were treated with 1.25 or 5 µM of garcinone C for 10 days. The results demonstrated that garcinone C significantly delayed the ability of NPC cells to form colonies (P<0.01), in a dose-dependent manner (Fig. 3) .
Garcinone C slightly induces the apoptosis of NPC cells.
Having found that garcinone C caused inhibition of cell growth, we investigated whether this was due to the induction of apoptosis in the CNE1 and CNE2 cells. Cells were treated with 5, 7.5 and 10 µM of garcinone C or DMSO (control) for 24, 48 and 72 h. Subsequently, the cells were stained with Annexin V and PI, and subjected to flow cytometry to quantify the amount of apoptotic cells. The results revealed that garcinone C caused a slight increase in the apoptotic cell population in CNE1 and CNE2 cells (Fig. 4) . However, the modest increase in the number of apoptotic cells after garcinone C treatment suggest that apoptosis may not be the major reason for the cell growth inhibition.
Garcinone C induces S phase cell cycle arrest.
To assess whether garcinone C induces cell growth inhibition via alterations in cell cycle progression, we evaluated the effect of garcinone C on the cell cycle. As shown in Fig. 5 , there was a significant decrease in the proportion of cells in the G 0 /G 1 phase, and a significant increase in the proportion of cells in the S phase after cells were treated with garcinone C, vs. the control. For example (Fig. 5B) , the majority of control-treated CNE2 cells were in the G 0 /G 1 phase (53.38±0.55%), with a G 2 /M-phase fraction of 18.45±0.38%, and the remaining control cells (28.17±0.93%) were found to be in the S phase. However, garcinone C treatment produced a shift in the DNA content histogram. The G 0 /G 1 phase fraction decreased significantly to 47.23±0.93% after 24 h of 10 µM garcinone C treatment, 14.33±0.25% after 48 h of 10 µM garcinone C treatment, and 4.03±0.08% after 72 h of 10 µM garcinone C treatment. The decrease in the G 0 /G 1 -phase fraction was offset by a rise in the S-phase fraction, which increased from 28.17±0.93 to 42.99±0.88% after 24 h of treatment, 71.47±0.45% after 48 h of treatment, and 71.73±0.15% after 72 h of treatment. These results indicated that garcinone C efficiently inhibited the cell division by arresting cells in the S phase, suggesting that the inhibition of NPC cell proliferation by garcinone C is the result of cell cycle blockade.
High-dose garcinone C induces cell necrosis in a time-dependent manner. Next, we examined cells for ultrastructural differences using TEM. As shown in Fig. 6 , DMSO-treated control CNE1 and HONE1 cells exhibited normal morphology, with microvilli on the cell surface, abundant mitochondria and ribosomes. Upon exposure to 10 µM of garcinone C, cells exhibited a time-dependent increase in necrotic morphology, including cell swelling, rough endoplasmic reticulum degranulation, endoplasmic reticulum dilatation, mitochondrial swelling, vacuolar degeneration and loss of microvilli.
Garcinone C affects the expression levels of cell cycle-related proteins. Having noted that garcinone C induces cell cycle arrest in NPC cells, we investigated whether garcinone C could regulate the expression levels of cell cycle-related proteins. In agreement, a decrease in cyclin B1, cyclin D1, cyclin E2, cdc2 and CDK7 expression was observed in a dose-and time-dependent manner after treatments of 5, 7.5 and 10 µM garcinone C for 24, 48 and 72 h in CNE1, CNE2, HK1 and HONE1 cells (Fig. 7) . Additionally, an increase in ataxia telangiectasia and Rad3 related protein (ATR) expression was observed in CNE1 and HK1 cells. Together, our data indicated that garcinone C induced cell cycle arrest via the downregulation of cyclin B1, cyclin D1, cyclin E2, cdc2 and CDK7, presumably through ATR activation. Effect of garcinone C on cell cycle-related proteins in CNE1, CNE2, HK1, and HONE1 cells. Total cell lysates were prepared and subjected to SDS-PAGE followed by western blot analysis. Membranes were probed with anti-ATR, cyclin B1, cyclin D1, cyclin E2, cdc2, CDK7 and GAPDH. GAPDH was used as a loading control. The experiment was repeated three times with similar results.
Garcinone C decreases the expression level of Stat3 and increases the expression level of 4E-BP1.
To further evaluate the molecular mechanisms involved in the anticancer activity of garcinone C, we assessed the involvement of several key signal transduction pathways implicated in tumor progression by western blot analysis. As shown in Fig. 8 , our results showed that treatment of CNE1 cells with garcinone C did not significantly affect the protein levels of mTOR, GSK-3β, AMPKα, DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), Histone H2B, AKT, or Stat5 in a time-or dose-dependent manner. However, we noted a decrease in the levels of Stat3 and an increase in the levels of 4E-BP1 in the four NPC cell lines treated with garcinone C (Fig. 9) .
Discussion
In the present study, we demonstrated that garcinone C significantly inhibited the cell proliferation and colony-formation ability of NPC cells in vitro, in a dose-and time-dependent manner. Mechanistically, the inhibitory effect of garcinone C on cell growth could be ascribed to the arrest of the cell cycle in the S phase.
DNA damage checkpoints play an important role in normal nasopharyngeal epithelial cells by protecting them from genome instability and tumorigenesis. In NPC, targeting activation of the DNA damage checkpoint is a major therapeutic strategy (18) . Moreover, increased DNA damage tolerance is one of the reasons for the development of drug resistance (19) . In this study, we detected the expression levels of DNA damage-related proteins, ATR and DNA-PKcs after treatments with garcinone C. The results revealed that garcinone C induced the expression level of ATR, but did not effect the expression level of DNA-PKcs. ATR is a phosphatidylinositol 3 kinase-related kinase (PIKK) family member that is activated in response to sensing DNA damage/replication blocks and triggers the DNA damage checkpoint, leading to the arrest of cell cycle progression (20) . Although cell growth and cell cycle inhibition are complex processes, which involve many pathways, activation of the DNA damage checkpoint by ATR accumulation could be one of the mechanisms responsible for the ability of garcinone C to inhibit cell growth and induce cell cycle arrest. Therefore, garcinone C might be a new compound for targeting the DNA damage checkpoint in NPC cells and could be a novel drug candidate to use in combination with other agents to enhance the antitumor activity of other chemotherapies.
Cells die through two main processes: necrosis, defined as cell death due to unexpected and accidental cell damage, or apoptosis. In this study, tumor cell necrosis, morphologically characterized by a gain in cell volume, swelling of organelles, and subsequent loss of intracellular contents, was detected within 72 h of 10 µM high-dose garcinone C treatment. However, the presence of necrosis can only indicate that a cell has died, but not necessarily how death occurred (21) . Moreover, necrotic pathways are poorly defined and require further elucidation. Therefore, our data indicate that garcinone C-induced NPC cell necrosis is associated with S phase cell cycle arrest, but further investigation is required.
The signal transducer and activator of transcription (Stat) family, including Stat1-6, regulates many aspects of cell growth, survival and differentiation. In particular, Stat3 is constitutively activated in many different types of cancer, plays a pivotal role in tumor growth, and possesses oncogenic poten- Figure 9 . Effects of garcinone C on expression levels of Stat3 and 4E-BP1 in CNE1, CNE2, HK1 and HONE1 cells. Cells were treated with 5, 7.5 and 10 µM of garcinone C or 1/2,000 DMSO (control) for 24, 48 and 72 h. At the end of treatments, total cell lysates were prepared and subjected to SDS-PAGE followed by western blot analysis. Membranes were probed with anti-Stat3, 4E-BP1 and GAPDH. GAPDH was used as a loading control. The experiment was repeated three times with similar results. Figure 8 . Western blot analysis showed that the expression levels of mTOR, GSK-3β, AMPKα, DNA-PKcs, Histone H2B, AKT and Stat5 were not affected by garcinone C in CNE1 cells. CNE1 cells were treated with 5, 7.5 and 10 µM of garcinone C or 1/2,000 DMSO (control) for 24, 48 and 72 h. Cells were lysed and total protein was collected for western blot analysis.
tial (22, 23) . In this study, we found that garcinone C did not affect the expression level of Stat5, but significantly inhibited the expression of Stat3 in four NPC cell lines, in a time-and dose-dependent manner. Thus, our findings suggested that garcinone C inhibits NPC cell growth through a mechanism that likely involves Stat3 inhibition.
The eukaryotic translation initiation factor 4E (elF4E)-binding protein 1 (4E-BP1), a translation repressor protein, contributes to the inhibition of protein synthesis and growth inhibition of tumor cells (24) . Consistent with our results, it has been reported that some natural compounds could enhance the expression of 4E-BP1 and trigger tumor cell death (25) . 4E-BP1 is also regulated by AKT/GSK-3β/AMPKα/mTOR signaling pathways (26) . However, our western blot results showed that although garcinone C upregulated the expression of 4E-BP1, there was no effect on the expression level of AKT, GSK-3β, AMPKα, or mTOR, which suggested that garcinone C might target 4E-BP1 via an AKT/GSK-3β/AMPKα/mTOR-independent pathway.
In conclusion, garcinone C treatment was able to decrease the cell viability and colony-formation ability in CNE1 (well-differentiated squamous cell carcinoma), CNE2 (non-keratinizing carcinoma), HK1 (well-differentiated squamous cell carcinoma) and HONE1 (undifferentiated carcinoma) NPC cells. Furthermore, garcinone C was able to induce S phase cell cycle arrest in all NPC cell lines, and downregulate the expression levels of cell cycle-related proteins cyclin B1, cyclin D1, cyclin E2, cdc2 and CDK7, presumably through ATR activation. Our findings also demonstrated that garcinone C decreased the expression level of Stat3 and increased the expression level of 4E-BP1. Moreover, a high-dose of garcinone C induced necrosis in NPC cells. Taken together, these results revealed that the potential use of garcinone C as a chemotherapeutic agent in NPC warrants further investigation.
